<table id="ID445" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 4Clinically Relevant Interactions Affecting Omeprazole When Co-Administered with Other Drugs</caption>
<col width="35%"></col>
<col width="65%"></col>
<tbody>
<tr>
<td align="justify" stylecode=" Lrule Botrule Toprule" valign="top">CYP2C19 or CYP3A4 Inducers<br/>
</td>
<td align="justify" stylecode=" Rrule Botrule Toprule" valign="top">
<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact</content>
<content stylecode="italics">:</content>
<br/>
</td>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Decreased exposure of omeprazole when used concomitantly with strong inducers [see Clinical Pharmacology (<linkhtml href="#ID222">12.3</linkhtml>)]. </td>
</tr>
<tr>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Intervention</content>
<content stylecode="italics">:</content>
<br/>
</td>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">St. John’s Wort, rifampin: Avoid concomitant use with omeprazole [see Warnings And Precautions (<linkhtml href="#ID379">5.9</linkhtml>)]. Ritonavir-containing products: see prescribing information for specific drugs. </td>
</tr>
<tr>
<td align="justify" stylecode=" Lrule Botrule Toprule" valign="top">
<content stylecode="bold">CYP2C19 </content>
<content stylecode="bold">or </content>
<content stylecode="bold">CYP3A4 </content>
<content stylecode="bold">Inhibitors</content>
<br/>
</td>
<td align="justify" stylecode=" Rrule Botrule Toprule" valign="top">
<br/>
</td>
</tr>
<tr>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Clinical </content>
<content stylecode="italics">Impact</content>
<content stylecode="italics">:</content>
<br/>
</td>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Increased exposure of omeprazole [see Clinical Pharmacology (<linkhtml href="#ID222">12.3</linkhtml>)]. </td>
</tr>
<tr>
<td align="justify" stylecode=" Lrule Rrule Botrule Toprule" valign="top">
<content stylecode="italics">Intervention</content>
<content stylecode="italics">:</content>
<br/>
</td>
<td align="left" stylecode=" Lrule Rrule Botrule Toprule" valign="top">Voriconazole: Dose adjustment of omeprazole is not normally required. However, in patients with Zollinger-Ellison syndrome, who may require higher doses, dose adjustment may be considered.<br/>See prescribing information for voriconazole.<br/>
</td>
</tr>
</tbody>
</table>